The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect
Daniel Andrews,
Simon Ducharme,
Howard Chertkow
et al.
Abstract:INTRODUCTIONThe Phase 3 trial CLARITY AD found that lecanemab slowed cognitive decline by a statistically significant 27% vs. placebo. However, the subgroup analysis indicated a significant sex difference in the effect, and recent work has implied that lecanemab has either no or limited effectiveness in females. To resolve this ambiguity, we used simulations constrained by the trial design to determine whether the difference could be explained by known sex differences in Alzheimer’s progression, or as an isola… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.